Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 8Breast Neoplasms 7Prostatic Neoplasms 6Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 5Glioma 5Astrocytoma 5Oropharyngeal Neoplasms 4Esophageal Neoplasms 4Carcinoma 4Burkitt Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Rectal Neoplasms 3Neoplasm Metastasis 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Pancreatic Neoplasms 2Neoplasms 2Mouth Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Liposarcoma 2Laryngeal Neoplasms 2Hodgkin Disease 2Gliosarcoma 2Ganglioneuroblastoma 2

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Radiation × 30 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡